The share price of Myriad Genetics, Inc. [NASDAQ: MYGN] inclined by $25.50, presently trading at $23.20. The company’s shares saw 5.12% gains compared to the lowest price in the period of the last 52 weeks, set at $22.07 recorded on 15/08/2019. The last few days have been tough to the share price as MYGN fall by -49.41% during the last week, even though the stock is still down by -50.75% compared to -22.66 of all time high it touched on 08/13/19. However, the stock had a poor performance during the past 3 months, roughly losing -11.79%, while additionally dropping -44.74% during the last 12 months. Myriad Genetics, Inc. is said to have a 12-month price target set at $38.30. That means that the stock has a strong potential to acquire 15.1% increase from the current trading price.
Myriad Genetics, Inc. [NASDAQ:MYGN]: Analyst Rating and Earnings
Stock market traders frequently keep their eyes on what Wall Street experts as it relates to a potential investment. For Myriad Genetics, Inc. [MYGN], the most recent analyst consensus recommendation available since its latest financial results for the quarter ending in June. On average, stock market experts give MYGN an Hold rating. Its stock price has been found in the range of 22.07 to 50.44. This is compared to its latest closing price of $25.50.
Wall Street analysts provide their ratings on a scale of 1 to 5, and the current average score for Myriad Genetics, Inc. [MYGN] is sitting at 3.00. This is compared to 1 month ago, when its average rating was 2.82.
For the quarter ending in Jun-19 Myriad Genetics, Inc. [MYGN] generated $0.22 billion in sales. That’s 2.55% lower than the average estimate of $0.22 billion as provided by Wall Street analysts. The three indicators above suggest that overall, this stock is demonstrating a mixed bag of positive appeal and some drawbacks, making it a somewhat risky investment that also has the potential to generate high ROI in the long run.
Keep your eyes peeled for the soon-to-be-published financial results of this company, which are expected to be made public on Tue 5 Nov (In 82 Days).
Fundamental Analysis of Myriad Genetics, Inc. [MYGN]
Now let’s turn to look at profitability: with a current Operating Margin for Myriad Genetics, Inc. [MYGN] sitting at +7.44 and its Gross Margin at +77.06, this company’s Net Margin is now 1.80%. These metrics indicate that this company is not generating as much profit, after accounting for expenses, compared to its market peers.
This company’s Return on Total Capital is 6.21, and its Return on Invested Capital has reached 10.30%. Its Return on Equity is 15.04, and its Return on Assets is 10.31. These metrics suggest that this Myriad Genetics, Inc. does a poor job of managing its assets, and likely won’t be able to provide successful business outcomes for its investors in the near term.
Turning to investigate this organization’s capital structure, Myriad Genetics, Inc. [MYGN] has generated a Total Debt to Total Equity ratio of 0.96. Similarly, its Total Debt to Total Capital is 0.95, while its Total Debt to Total Assets stands at 0.76. Looking toward the future, this publicly-traded company’s Long-Term Debt to Equity is 0.96, and its Long-Term Debt to Total Capital is 0.95. This company has a healthy balance between its debt and its current holdings, suggesting it is a reliable investment due to its ability to leverage debt in an efficient way.
What about valuation? This company’s Enterprise Value to EBITDA is 30.77 and its Total Debt to EBITDA Value is 0.08. The Enterprise Value to Sales for this firm is now 4.03, and its Total Debt to Enterprise Value stands at 0.00. Myriad Genetics, Inc. [MYGN] has a Price to Book Ratio of 2.73, a Price to Cash Flow Ratio of 23.22 and P/E Ratio of 391.23. These metrics suggest that this publicly-traded organization will not likely result in investment gains.
Shifting the focus to workforce efficiency, Myriad Genetics, Inc. [MYGN] earns $321,917 for each employee under its payroll. Similarly, this company’s Receivables Turnover is 7.24 and its Total Asset Turnover is 0.61. This publicly-traded organization’s liquidity data is also interesting: its Quick Ratio is 2.86 and its Current Ratio is 3.19. This company, considering these metrics, has a healthy ratio between its short-term liquid assets and its short-term liabilities, making it a less risky investment.
Myriad Genetics, Inc. [MYGN] has 73.99M shares outstanding, amounting to a total market cap of $1.72B. Its stock price has been found in the range of 22.07 to 50.44. At its current price, it has moved down by -54.00% from its 52-week high, and it has moved up 5.12% from its 52-week low.
This stock’s Beta value is currently 0.65, which indicates that it is 8.80% more volatile that the wider market. This stock’s Relative Strength Index (RSI) is at 33.20. This RSI score is good, suggesting this stock is neither overbought or oversold.
Conclusion: Is Myriad Genetics, Inc. [MYGN] a Reliable Buy?
Shares of Myriad Genetics, Inc. [MYGN], on the whole, present investors with both positive and negative signals. Wall Street analysts have mixed reviews when it comes to the 12-month price outlook, and this company’s financials show a combination of strengths and weaknesses. Based on the price performance, this investment is somewhat risky while presenting reasonable potential for ROI.